Q2 FY2026 EarningsQ2 FY26 beat consensus significantly across all key metrics: revenue $23.0B vs. $20.7B expected (+11.1%), and non-GAAP EPS $8.38 vs. $6.58 expected (+27.3%). Growth was primarily driven by Mounjaro and Zepbound, which saw massive volume increases despite realized price declines. Management raised FY26 revenue guidance to $85-87B (prior $82-85B), though the EPS range was narrowed to $35.50-$36.50 due to $3.03/share in acquired IPR&D charges.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Eli Lilly(LLY) the Revenue is 22.97 B (+47.67%), Beat estimate;the EBIT is 9.806 B (+40.31%), Beat estimate;the EPS is 7.94 (+26.23%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
22.97B47.67%
20.69B32.96%
+2.29B14.71%
EBITExceed expectations
9.81B40.31%
7.72B10.39%
+2.09B29.92%
EPSExceed expectations
7.9426.23%
7.543319.93%
+0.39676.30%
Upcoming earnings report - Q3 FY2026
Available dateOct 29, 2026
Estimate Revenue$22.22 B
Estimate EBIT$10.87 B
Estimate EPS$9.2466
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf